Ustekinumab
Active ingredient: Ustekinumab-Aekn
In short: Ustekinumab-aekn is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Ustekinumab-aekn is indicated for the treatment of adults and pediatric patients 6 years of age
What is Ustekinumab used for?
Ustekinumab-aekn is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Ustekinumab-aekn is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis.
Ustekinumab-aekn is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease.
Ustekinumab-aekn is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
Ustekinumab dosage
Subcutaneous Adult Dosage Regimen
For patients weighing 100 kg or less, the recommended dosage is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks.
For patients weighing more than 100 kg, the recommended dosage is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks.
In subjects weighing more than 100 kg, 45 mg was also shown to be efficacious. However, 90 mg resulted in greater efficacy in these subjects
.
Subcutaneous Pediatric Dosage Regimen
Administer Ustekinumab-aekn subcutaneously at Weeks 0 and 4, then every 12 weeks thereafter.
The recommended dose of Ustekinumab-aekn for pediatric patients 6 years of age and older with plaque psoriasis based on body weight is shown below (Table 1).
Body Weight of Patient at the Time of Dosing | Recommended Dose
less than 60 kg | 0.75 mg/kg
60 kg to 100 kg | 45 mg
more than 100 kg | 90 mg
For pediatric patients weighing less than 60 kg, the administration volume for the recommended dose (0.75 mg/kg) is shown in Table 2; withdraw the appropriate volume from the vial.
Body Weight (kg) at the time of dosing | Dose (mg) | Volume of injection (mL)
15 | 11.3 | 0.12
16 | 12 | 0.13
17 | 12.8 | 0.14
18 | 13.5 | 0.15
19 | 14.3 | 0.16
20 | 15 | 0.17
21 | 15.8 | 0.17
22 | 16.5 | 0.18
23 | 17.3 | 0.19
24 | 18 | 0.20
25 | 18.8 | 0.21
26 | 19.5 | 0.22
27 | 20.3 | 0.22
28 | 21 | 0.23
29 | 21.8 | 0.24
30 | 22.5 | 0.25
31 | 23.3 | 0.26
32 | 24 | 0.27
33 | 24.8 | 0.27
34 | 25.5 | 0.28
35 | 26.3 | 0.29
36 | 27 | 0.3
37 | 27.8 | 0.31
38 | 28.5 | 0.32
39 | 29.3 | 0.32
40 | 30 | 0.33
41 | 30.8 | 0.34
42 | 31.5 | 0.35
43 | 32.3 | 0.36
44 | 33 | 0.37
45 | 33.8 | 0.37
46 | 34.5 | 0.38
47 | 35.3 | 0.39
48 | 36 | 0.4
49 | 36.8 | 0.41
50 | 37.5 | 0.42
51 | 38.3 | 0.42
52 | 39 | 0.43
53 | 39.8 | 0.44
54 | 40.5 | 0.45
55 | 41.3 | 0.46
56 | 42 | 0.46
57 | 42.8 | 0.47
58 | 43.5 | 0.48
59 | 44.3 | 0.49
* Refer to 2.2 Psoriatic Arthritis; Subcutaneous Pediatric Dosage Regimen.
Subcutaneous Adult Dosage Regimen
The recommended dosage is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks.
For patients with co-existent moderate-to-severe plaque psoriasis weighing more than 100 kg, the recommended dosage is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks.
Subcutaneous Pediatric Dosage Regimen
Administer Ustekinumab-aekn subcutaneously at Weeks 0 and 4, then every 12 weeks thereafter.
The recommended dose of Ustekinumab-aekn for pediatric patients 6 years of age and older with psoriatic arthritis, based on body weight, is shown below (Table 3). …
How to take Ustekinumab — instructions & advice from the label
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Infections
Inform patients that Ustekinumab-aekn may lower the ability of their immune system to fight infections and to contact their healthcare provider immediately if they develop any signs or symptoms of infection
.
Malignancies
Inform patients of the risk of developing malignancies while receiving Ustekinumab-aekn
.
Serious Hypersensitivity and Reactions
Inform patients that serious hypersensitivity reactions have been reported with intravenous and subcutaneous administration of ustekinumab products. Instruct patients to discontinue Ustekinumab-aekn and seek immediate medical attention if they experience any signs or symptoms of hypersensitivity reactions
.
Posterior Reversible Encephalopathy Syndrome (PRES)
Inform patients to immediately contact their healthcare provider if they experience signs and symptoms of PRES (which may include headache, seizures, confusion, or visual disturbances)
.
Immunizations
Inform patients that Ustekinumab-aekn can interfere with the usual response to immunizations and that they should avoid live vaccines
. …
Warnings & precautions
Do not take this medicine if: Ustekinumab-aekn is contraindicated in patients with clinically significant hypersensitivity to ustekinumab products or to any of the excipients in Ustekinumab-aekn
.
Ustekinumab products may increase the risk of infections and reactivation of latent infections. Serious bacterial, mycobacterial, fungal, and viral infections were observed in patients receiving ustekinumab products
.
Serious infections requiring hospitalization, or otherwise clinically significant infections, reported in clinical trials included the following:
Plaque Psoriasis:diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, gastroenteritis, and urinary tract infections.
Psoriatic arthritis:cholecystitis.
Crohn’s disease:anal abscess, gastroenteritis, ophthalmic herpes zoster, pneumonia, and listeria meningitis.
Ulcerative colitis:gastroenteritis, ophthalmic herpes zoster, pneumonia, and listeriosis.
Avoid initiating treatment with Ustekinumab-aekn in patients with any clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to initiating use of Ustekinumab-aekn in patients with a chronic infection or a history of recurrent infection.
Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur while on treatment with Ustekinumab-aekn and discontinue Ustekinumab-aekn for serious or clinically significant infections until the infection resolves or is adequately treated.
Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria (including nontuberculous, environmental mycobacteria), salmonella (including nontyphi strains), and Bacillus Calmette-Guerin (BCG) vaccinations. …
Ustekinumab side effects
The following serious adverse reactions are discussed elsewhere in the label:
Infections
Malignancies
Serious Hypersensitivity Reactions
Posterior Reversible Encephalopathy Syndrome (PRES)
Noninfectious Pneumonia
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adult Subjects with Plaque Psoriasis
The safety data reflect exposure to ustekinumab in 3117 adult subjects with plaque psoriasis, including 2414 exposed for at least 6 months, 1855 exposed for at least one year, 1653 exposed for at least two years, 1569 exposed for at least three years, 1482 exposed for at least four years and 838 exposed for at least five years.
Table 5 summarizes the adverse reactions that occurred at a rate of at least 1% with higher rates in the ustekinumab groups during the placebo-controlled period of Ps STUDY 1 and Ps STUDY 2
. …
Drug interactions
In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In trials in subjects with Crohn’s disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohn’s disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab.
The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e.g., IL-1, IL-6, TNFα, IFN) during chronic inflammation. Thus, use of ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of Ustekinumab-aekn in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed. …
About this medicine
Ustekinumab-aekn, a human IgG1κ monoclonal antibody, is a human interleukin-12 and -23 antagonist. Using DNA recombinant technology, ustekinumab-aekn is produced in a murine cell line (Sp2/0). The manufacturing process contains steps for the clearance of viruses. Ustekinumab-aekn is comprised of 1326 amino acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Daltons.
Ustekinumab-aekn injection is a sterile, preservative-free, clear and colorless to slightly yellow solution free of visible particles with pH of 5.7 to 6.3.
Ustekinumab-aekn for Subcutaneous Use
Available as 45 mg of ustekinumab-aekn in 0.5 mL and 90 mg of ustekinumab-aekn in 1 mL, supplied as a sterile solution in a single-dose prefilled syringe with a 29-gauge fixed 1/2 inch needle and as 45 mg of ustekinumab-aekn in 0.5 mL in a single-dose borosilicate Type I glass vial with a rubber stopper. Not made with natural rubber latex. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 052a3fb2-21c3-4c4e-a01e-afdd1accd1cd. Read the full official label on DailyMed.
Related medicines
Doxycycline Adalimumab Ketoconazole Levocetirizine Cyclosporine Tretinoin Brimonidine Dupilumab